ObGyn
Partner With Us
Advertisement
Conexiant chevron_right ObGyn chevron_right Study Explores Risk of Cervical Cancer in TMGD Individuals
From the Journals

Study Explores Risk of Cervical Cancer in TMGD Individuals

Researchers found "no increased risk of invasive cervical cancer or high-grade cervical intraepithelial neoplasia in transmasculine and gender-diverse (TMGD) [individuals] using gender-affirming hormone therapy," but added that the findings should be interpreted with caution.

Conexiant
article Full Article subject Summary summarize Notecard
  1. Researchers conducted a retrospective cohort study on the risk of cervical cancer in transmasculine and gender-diverse (TMGD) individuals undergoing testosterone treatment.
  2. No cases of cervical cancer were observed in the cohort, suggesting no higher risk in this population compared to cisgender women.
  3. Authors emphasized the need for further studies with longer follow-up periods and comprehensive data on HPV infection and screening practices.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.